A 6-year-old boy underwent a craniotomy with subtotal resection of the cerebellar vermian tumor. Microscopic examination showed medulloblastoma. Brain magnetic resonance imaging after resection did not show residual disease. He subsequently received four cycles of ICE (ifosfamide, cisplatin, and etoposide) chemotherapy followed by whole craniospinal (24 Gy) and local (30 Gy) radiation therapy. He eventually received tandem highdose chemotherapy. Conditioning regimens for the first and the second were carboplatin (1200 mg/m /kg in the second, respectively. Engraftment after the second autologous PBSCT was achieved on day 11. Brain magnetic resonance imaging on day 25 of the second autologous PBSCT showed no evidence of recurrence.
On day 64 of the second autologous PBSCT, he developed sudden dyspnea with 90% oxygen saturation in room air. A chest X-ray film showed a ground-glass appearance in both lungs. Chest computed tomography scan also showed bilateral areas of ground-glass opacities, and no centrilobular micronodule. Aspergillus, candida, and cryptococcal antigen for the serum were negative. The b-D-glucan level was significantly elevated (234.4 pg/ml). Intravenous cotrimoxazole therapy was initiated, because pneumocystis pneumonia was thought to have caused pneumonia based on the clinical course. He was placed on mechanical ventilation and methylprednisolone pulse therapy (30 mg/kg Â 3 days) was started on day 72. His respiratory condition improved quickly with these treatments and mechanical ventilation was discontinued on day 77. Although polymerase chain reaction for Pneumocystis jirovecii in bronchoalveolar lavage fluid was negative, we diagnosed the cause of his pulmonary disorder had been pneumocystis pneumonia. His respiratory condition deteriorated again on day 82. Despite the second course of methylprednisolone pulse and continued cotrimoxazole therapy, he was placed on mechanical ventilation again on day 85 ( Figure 1a) . No pathogenic bacterial, fungal, or viral agents, including cytomegalovirus were identified by microbiological cultures and serological studies. The b-D-glucan level was also decreased to 33.4 pg/ml. Although various antibiotics, ganciclovir, antifungal drugs, and cotrimoxazole therapy were continued, his pulmonary oxygenation became worse day-by-day. He died on day 133 of the second autologous PBSCT because of respiratory failure (Figure 1b ).
An autopsy was performed with the consent of his parents. Microscopically, organizing diffuse alveolar damage was seen, and nuclear enlargement, hyperchromasia, and pleomorphism were seen along alveolar and bronchial epithelium. This cytologic atypia was seen not only in the lung, but also in the urothelium of the renal pelvis. There was no evidence of bacterial, fungal, or viral infection. These pathological findings were consistent with busulfan-induced lung disease. Organizing diffuse alveolar damage is the most common manifestation of busulfan lung toxicity and is associated with bronchiolar and alveolar epithelium atypia. 1 This cytologic atypia is often seen extrapulmonary sites, including urinary bladder, breast, and uterine cervix. 1 The incidence of pulmonary toxicity after high-dose oral busulfan therapy before stem cell transplantation has been reported to be 3.6%. 2 Corticosteroids are effective for treating this disease to various degrees. Although some patients improve, others progress and die. 1 It has become evident posthumously that busulfan areas under the drug plasma concentration-time curve (AUC) levels at the 1st and 9th doses were significantly elevated (2353 mM Â min, 2347 mM Â min) (target AUC; 900-1500 mM Â min). Busulfan concentrations for the 1st and 9th doses and the accumulation of intravenous busulfan in plasma were assayed using a high-performance liquid chromatography system (Figure 2) . 3 Plasma concentrations were analyzed by the non-compartmental method using WinNonlin (version 5.2.1; Pharsight Corp., Mountain View, CA, USA). The AUC from time 0 to infinity (AUC inf ) for the 1st dose and at steady state (AUC ss ) for the 9th dose was calculated using linear trapezoidal rule. The relationship between high busulfan AUC levels and the occurrence of busulfan-induced lung disease has not been established, 4 although high busulfan AUC levels are commonly associated with hepatic veno-occlusive disease. 5 The cause of high busulfan AUC levels in our patient is still unclear. He did not have the distinct liver or renal disorder at the time of busulfan administration. Busulfan is metabolized in the liver through conjugation with glutathione by glutathione S-transferase (GST) enzymes. 6 GSTA1 is the predominant isoform of GST, which catalyzes the conjugation of busulfan with glutathione. Polymorphisms in GSTA1 are thought to be associated with alterations in the pharmacokinetics of busulfan.
Johnson et al. 7 reported that the GSTA1*B variant had a 2.6-fold higher busulfan AUC level than other variants after intravenous busulfan exposure in the pediatric population. Our patient's genotype of the promoter region of GST A1 by DNA sequencing was GSTA1*A diplotype (-567T, -69C, -52G) which is thought to be more active than the GSTA1 *A/*B. Nevertheless, busulfan AUC levels were significantly elevated. This may indicate that polymorphisms other than GSTA1 polymorphisms may affect busulfan metabolism.
Intravenous busulfan should have a much more predictable pharmacokinetic profile than oral busulfan. Treatment with a fixed dose of 0.80 mg/kg intravenous busulfan achieved the target AUC level (900-1500 mM Â min) in 80% of adult patients. 8 The remaining 20% were very close to achieving the target level. 8 A recent European study showed that 91% of children achieved target AUC levels by weight-based dosing. 9 They concluded that this weight-based dosing in children is sufficient without therapeutic drug monitoring and dose adjustment. Our patient received intravenous busulfan according to his body weight, as in the European study. However, his busulfan AUC levels were higher than has been reported elsewhere in the literature. 9, 10 To avoid unexpectedly high busulfan AUC levels, therapeutic drug monitoring and dose adjustment should be recommended for all patients who are treated with high-dose busulfan. When therapeutic drug monitoring is not applicable, test dosing of intravenous busulfan before high-dose therapy would be preferable.
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